NCT03927456: A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 3
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy)

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have received at least 1 line of chemotherapy & 1 line of hormone therapy for metastatic disease
Exclusions: Patients who received prior treatment with any CDK4/6 inhibitor, everolimus, or fulvestrant

Comments are closed.

Up ↑